The Impact of Histotripsy Technique in Tumor Ablation - a Systematic Review


  • Areej D. Alghamdi Scientific Research Center, Ministry of Defense for Health Services, Riyadh, Saudi Arabia
  • Abdullah Sahrah Health Studies Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia


Histotripsy, Tumor ablation, Immune system activation, Preclinical models, Adverse events


According to a study conducted in the U.S., cancer affects more than 700,000 individuals worldwide each year, with 35,660 new cases diagnosed in the U.S. in 2015 alone. However, there are only a few standard treatment choices, which include radiation, chemotherapy, and surgery. This systematic review report on the impact of histotripsy in tumor ablation. In this paper, the effectiveness, safety and advantages of histotripsy compared to other methods are explored. A search was done on ScienceDirect, PubMed, Google Scholar, and Scopus databases for articles published from the date of inception of the databases to 21st March 2023. Reference lists of identified studies were also screened. Non-duplicate articles were identified, and 12 articles were included for thematic analysis. During the analysis, different effects of histotripsy were categorized. This categorization led to the realization of the effectiveness, immunological effects, safety and advantages of histotripsy compared to the therapeutic options. Histotripsy is effective and safe treatment for various types of cancer, including cholangiocarcinoma, pancreatic cancer, breast cancer, colorectal cancer, osteosarcoma, and hepatocellular carcinoma (HCC).


R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, ‘Cancer Statistics, 2021’, CA Cancer J Clin, vol. 71, no. 1, pp. 7–33, Jan. 2021, doi: 10.3322/caac.21654.

M. Hidalgo, ‘Pancreatic cancer’, N Engl J Med, vol. 362, no. 17, pp. 1605–1617, Apr. 2010, doi: 10.1056/NEJMra0901557.

S. Gillen, T. Schuster, C. Meyer Zum Büschenfelde, H. Friess, and J. Kleeff, ‘Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages’, PLoS Med, vol. 7, no. 4, p. e1000267, Apr. 2010, doi: 10.1371/journal.pmed.1000267.

A. J. Fakiris et al., ‘Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study’, Int J Radiat Oncol Biol Phys, vol. 75, no. 3, pp. 677–682, Nov. 2009, doi: 10.1016/j.ijrobp.2008.11.042.

M. Kudo, ‘Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010’, Oncology, vol. 78 Suppl 1, pp. 113–124, Jul. 2010, doi: 10.1159/000315239.

E. Lanza et al., ‘Percutaneous Image-Guided Cryoablation of Breast Cancer: A Systematic Review’, J Vasc Interv Radiol, vol. 26, no. 11, pp. 1652-1657.e1, Nov. 2015, doi: 10.1016/j.jvir.2015.07.020.

A. Giorgio, L. Tarantino, G. de Stefano, C. Coppola, and G. Ferraioli, ‘Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-year experience with 336 patients at a single center’, AJR Am J Roentgenol, vol. 184, no. 1, pp. 207–211, Jan. 2005, doi: 10.2214/ajr.184.1.01840207.

J. A. Marrero and S. Pelletier, ‘Hepatocellular carcinoma’, Clin Liver Dis, vol. 10, no. 2, pp. 339–351, ix, May 2006, doi: 10.1016/j.cld.2006.05.012.

E. Liapi and J.-F. H. Geschwind, ‘Transcatheter and ablative therapeutic approaches for solid malignancies’, J Clin Oncol, vol. 25, no. 8, pp. 978–986, Mar. 2007, doi: 10.1200/JCO.2006.09.8657.

H. Fukuda et al., ‘Treatment of small hepatocellular carcinomas with US-guided high-intensity focused ultrasound’, Ultrasound Med Biol, vol. 37, no. 8, pp. 1222–1229, Aug. 2011, doi: 10.1016/j.ultrasmedbio.2011.04.020.

K. B. Bader, E. Vlaisavljevich, and A. D. Maxwell, ‘For Whom the Bubble Grows: Physical Principles of Bubble Nucleation and Dynamics in Histotripsy Ultrasound Therapy’, Ultrasound Med Biol, vol. 45, no. 5, pp. 1056–1080, May 2019, doi: 10.1016/j.ultrasmedbio.2018.10.035.

Z. Xu, T. L. Hall, E. Vlaisavljevich, and F. T. Lee, ‘Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound’, Int J Hyperthermia, vol. 38, no. 1, pp. 561–575, 2021, doi: 10.1080/02656736.2021.1905189.

E. Vlaisavljevich et al., ‘Image-guided non-invasive ultrasound liver ablation using histotripsy: feasibility study in an in vivo porcine model’, Ultrasound Med Biol, vol. 39, no. 8, pp. 1398–1409, Aug. 2013, doi: 10.1016/j.ultrasmedbio.2013.02.005.

A. R. Smolock et al., ‘Robotically Assisted Sonic Therapy as a Noninvasive Nonthermal Ablation Modality: Proof of Concept in a Porcine Liver Model’, Radiology, vol. 287, no. 2, pp. 485–493, May 2018, doi: 10.1148/radiol.2018171544.

E. Vlaisavljevich et al., ‘Non-Invasive Liver Ablation Using Histotripsy: Preclinical Safety Study in an In Vivo Porcine Model’, Ultrasound Med Biol, vol. 43, no. 6, pp. 1237–1251, Jun. 2017, doi: 10.1016/j.ultrasmedbio.2017.01.016.

G. R. Schade, Y.-N. Wang, S. D’Andrea, J. H. Hwang, W. C. Liles, and T. D. Khokhlova, ‘Boiling Histotripsy Ablation of Renal Cell Carcinoma in the Eker Rat Promotes a Systemic Inflammatory Response’, Ultrasound Med Biol, vol. 45, no. 1, pp. 137–147, Jan. 2019, doi: 10.1016/j.ultrasmedbio.2018.09.006.

G. R. Schade et al., ‘Histotripsy focal ablation of implanted prostate tumor in an ACE-1 canine cancer model’, J Urol, vol. 188, no. 5, pp. 1957–1964, Nov. 2012, doi: 10.1016/j.juro.2012.07.006.

T. Gerhardson et al., ‘Histotripsy Clot Liquefaction in a Porcine Intracerebral Hemorrhage Model’, Neurosurgery, vol. 86, no. 3, pp. 429–436, Mar. 2020, doi: 10.1093/neuros/nyz089.

K. B. Bader, S. A. Hendley, and V. Bollen, ‘Assessment of Collaborative Robot (Cobot)-Assisted Histotripsy for Venous Clot Ablation’, IEEE Trans Biomed Eng, vol. 68, no. 4, pp. 1220–1228, Apr. 2021, doi: 10.1109/TBME.2020.3023630.

T. A. Bigelow, C. L. Thomas, H. Wu, and K. M. F. Itani, ‘Impact of High-Intensity Ultrasound on Strength of Surgical Mesh When Treating Biofilm Infections’, IEEE Trans Ultrason Ferroelectr Freq Control, vol. 66, no. 1, pp. 38–44, Jan. 2019, doi: 10.1109/TUFFC.2018.2881358.

M. J. Page et al., ‘The PRISMA 2020 statement: an updated guideline for reporting systematic reviews’, BMJ, vol. 372, p. n71, Mar. 2021, doi: 10.1136/bmj.n71.

‘BestBETs - BETs CA Worksheets’. Accessed: Mar. 24, 2023. [Online]. Available:

V. Braun and V. Clarke, ‘Using thematic analysis in psychology’, Qualitative Research in Psychology, vol. 3, no. 2, pp. 77–101, Jan. 2006, doi: 10.1191/1478088706qp063oa.

A. Hendricks-Wenger et al., ‘Histotripsy for the Treatment of Cholangiocarcinoma in a Patient-Derived Xenograft Mouse Model’, Ultrasound Med Biol, vol. 48, no. 2, pp. 293–303, Feb. 2022, doi: 10.1016/j.ultrasmedbio.2021.10.002.

A. Hendricks-Wenger et al., ‘Histotripsy Ablation Alters the Tumor Microenvironment and Promotes Immune System Activation in a Subcutaneous Model of Pancreatic Cancer’, IEEE Trans Ultrason Ferroelectr Freq Control, vol. 68, no. 9, pp. 2987–3000, Sep. 2021, doi: 10.1109/TUFFC.2021.3078094.

M. Hoogenboom et al., ‘Impact of MR-guided boiling histotripsy in distinct murine tumor models’, Ultrason Sonochem, vol. 38, pp. 1–8, Sep. 2017, doi: 10.1016/j.ultsonch.2017.02.035.

G.-H. Nam et al., ‘Investigation of the Potential Immunological Effects of Boiling Histotripsy for Cancer Treatment’, Advanced Therapeutics, vol. 3, no. 8, p. 1900214, 2020, doi: 10.1002/adtp.201900214.

A. L. Pepple et al., ‘Spatiotemporal local and abscopal cell death and immune responses to histotripsy focused ultrasound tumor ablation’, Front Immunol, vol. 14, p. 1012799, 2023, doi: 10.3389/fimmu.2023.1012799.

T. Worlikar et al., ‘Histotripsy for Non-Invasive Ablation of Hepatocellular Carcinoma (HCC) Tumor in a Subcutaneous Xenograft Murine Model’, Annu Int Conf IEEE Eng Med Biol Soc, vol. 2018, pp. 6064–6067, Jul. 2018, doi: 10.1109/EMBC.2018.8513650.

T. Worlikar et al., ‘Impact of Histotripsy on Development of Intrahepatic Metastases in a Rodent Liver Tumor Model’, Cancers (Basel), vol. 14, no. 7, p. 1612, Mar. 2022, doi: 10.3390/cancers14071612.

L. N. Ruger et al., ‘Characterizing the Ablative Effects of Histotripsy for Osteosarcoma: In Vivo Study in Dogs’, Cancers (Basel), vol. 15, no. 3, p. 741, Jan. 2023, doi: 10.3390/cancers15030741.

E. Vlaisavljevich et al., ‘Non-Invasive Ultrasound Liver Ablation Using Histotripsy: Chronic Study in an In Vivo Rodent Model’, Ultrasound Med Biol, vol. 42, no. 8, pp. 1890–1902, Aug. 2016, doi: 10.1016/j.ultrasmedbio.2016.03.018.

S. Qu et al., ‘Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy’, J Immunother Cancer, vol. 8, no. 1, p. e000200, Jan. 2020, doi: 10.1136/jitc-2019-000200.




How to Cite

Areej D. Alghamdi, & Abdullah Sahrah. (2024). The Impact of Histotripsy Technique in Tumor Ablation - a Systematic Review. American Scientific Research Journal for Engineering, Technology, and Sciences, 97(1), 95–111. Retrieved from